natgillin/translations-raw huggingface dataset:
In a 30-day study (ACCOAST) in 4033 patients with NSTEMI with elevated troponin who were scheduled for coronary angiography followed by PCI within 2 to 48 hours after randomization, subjects who received prasugrel 30 mg loading dose on average 4 hours prior to coronary angiography followed by a 30 mg loading dose at the time of PCI (n=2037) had an increased risk of non-CABG peri-procedural bleeding and no additional benefit compared to patients receiving a 60 mg loading dose at the time of PCI (n=1996). 
U 30-dnevnom ispitivanju (ACCOAST) u 4033 bolesnika s NSTEMI i povišenim razinama troponina, koji su bili podvrgnuti koronarnoj angiografiji, a zatim i perkutanoj koronarnoj intervenciji, unutar 2 do 48 sati nakon randomizacije, ispitanici koji su primili udarnu dozu prasugrela od 30 mg u prosjeku 4 sata prije koronarne angiografije te zatim udarnu dozu od 30 mg u vrijeme perkutane koronarne intervencije (n=2037) imali su povećan rizik od krvarenja nevezanog za CABG tijekom postupka, a nisu imali nikakve dodatne koristi u odnosu na bolesnike koji su primili udarnu dozu od 60 mg u vrijeme perkutane koronarne intervencije (n=1996).
• Fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes (jaundice). 
• vrućicu i potkožne modrice koje se mogu pojaviti kao okrugle, crvene točkice veličine vrška pribadače, a mogu, ali ne moraju, biti popraćene neobjašnjivim izrazitim umorom, smetenošću, žutilom kože ili očiju (žutica) (vidjeti dio 2 'Što morate znati prije nego počnete uzimati Efient')
Patients < 60 kg Non-CABG-related TIMI major or minor bleeding rates: 
Bolesnici tjelesne težine < 60 kg Stope značajnih odnosno manjih krvarenja (prema TIMI kriterijima) nevezanih uz CABG:
Rifampicin (600 mg daily), a potent inducer of CYP3A and CYP2B6, and an inducer of CYP2C9, CYP2C19, and CYP2C8, did not significantly change the pharmacokinetics of prasugrel. 
Rifampicin (600 mg na dan), snažan induktor CYP3A i CYP2B6 te induktor CYP2C9, CYP2C19 i
In UA/NSTEMI patients, where coronary angiography is performed within 48 hours after admission, the loading dose should only be given at the time of PCI (see sections 4.4, 4.8 and 5.1). 
U bolesnika s UA/NSTEMI, u kojih se koronarna angiografija provodi unutar 48 sati nakon primitka u bolnicu, udarna doza smije se dati samo u vrijeme perkutane koronarne intervencije (vidjeti dijelove 4.4, 4.8 i 5.1).
Your doctor should prescribe a daily dose of 5 mg of Efient if you weigh less than 60 kg - renal (kidney) disease or moderate liver problems - taking certain types of medicines (see ‘Taking other medicines' below) - planned surgery (including some dental procedures) in the next seven days. 
- ako uzimate određene vrste lijekova (vidjeti ‘Drugi lijekovi i Efient' u nastavku) - ako imate zakazanu operaciju (uključujući i neke stomatološke zahvate) u sljedećih 7 dana.
2.2% (0.2% fatal) a 
2,2% (0,2% smrtonosna)a
9.0% (1.0% fatal) 
9,0% (1,0% smrtonosna)
Patients ≥60 kg and age <75 years 
Bolesnici tjelesne težine ≥ 60 kg i mlađi od 75 godina
0.9% (0.2% ICH*) 
0,9% (0,2% IKK*)
• Bleeding from a needle puncture site 
• krvarenje na mjestu uboda iglom
There is limited therapeutic experience in patients with renal impairment (see section 4.4). 
Terapijsko iskustvo u bolesnika s oštećenjem bubrega je ograničeno (vidjeti dio 4.4).
o If, after a careful individual benefit/risk evaluation by the prescribing physician, 
o ako nakon pažljive procjene koristi i rizika u svakog pojedinog bolesnika liječnik propisivač ocijeni da je primjena ovog lijeka neophodna u bolesnika u dobnoj skupini
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER OF 10 mg FILM-COATED TABLETS 
PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP BLISTER ZA 10 mg FILMOM OBLOŽENE TABLETE
Vascular Disorders Haematoma Respiratory, thoracic and mediastinal disorders 
Krvožilni poremećaji hematom Poremećaji dišnog sustava, prsišta i sredoprsja epistaksa hemoptiza
Clopidogrelb +ASA (N = 6716) 
Klopidogrel b +ASK (N = 6716)
Gastrointestinal haemorrhage 
Tablični prikaz nuspojava
Primary Composite Outcome Events Cardiovascular (CV) death, non fatal MI, or non fatal stroke 
Objedinjeni događaji iz primarne mjere ishoda: smrt zbog kardiovaskularnog (KV) uzroka, nesmrtonosni IM, ili nesmrtonosni moždani udar
including oral anticoagulants, clopidogrel, non-steroidal anti-inflammatory drugs (NSAIDs), and fibrinolytics. 
• koji istodobno primaju lijekove koji mogu povećati rizik od krvarenja, uključujući oralne antikoagulanse, klopidogrel, nesteroidne protuupalne lijekove (NSAIL) i fibrinolitike
In patients ≥60 kg and age <75 years, non-CABG-related TIMI major or minor bleeding rates were 3.6% for prasugrel and 2.8% for clopidogrel; rates for fatal bleeding were 0.2% for prasugrel and 0.1% for clopidogrel. 
TIMI kriterijima) nevezanih uz CABG iznosila je 3,6% uz prasugrel te 2,8% uz klopidogrel, dok je stopa smrtonosnih krvarenja bila 0,2% uz prasugrel i 0,1% uz klopidogrel.
CV death, nonfatal MI, or nonfatal stroke CV death Nonfatal MI Nonfatal stroke STEMI Primary Composite Outcome Events 
smrt zbog KV uzroka, nesmrtonosni IM, nesmrtonosni moždani udar smrt zbog KV uzroka nesmrtonosni IM nesmrtonosni moždani udar STEMI
1.0% (0.3% ICH*) 
1,0% (0,3% IKK*)
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER OF 5 mg FILM-COATED TABLETS 
PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP BLISTER ZA 5 mg FILMOM OBLOŽENE TABLETE
Efient 5 mg: Each tablet contains 5 mg of prasugrel (as hydrochloride). 
Efient 5 mg: Jedna tableta sadrži 5 mg prasugrela (u obliku prasugrelklorida).
10.1% (0% fatal) 
10,1% (0% smrtonosna)
treatment is deemed necessary in the ≥ 75 years age group then following a loading dose of 60 mg, a reduced maintenance dose of 5mg should be prescribed. 
≥ 75 godina, tada se nakon udarne doze od 60 mg mora propisati niža doza održavanja od 5 mg. o bolesnici tjelesne težine < 60 kg moraju primati nižu dozu održavanja od 5 mg.
Therefore, CYP3A inhibitors such as azol antifungals, HIV protease inhibitors, clarithromycin, telithromycin, verapamil, diltiazem, indinavir, ciprofloxacin, and grapefruit juice are not anticipated to have a significant effect on the pharmacokinetics of the active metabolite. 
Stoga se ne predviđa da bi inhibitori CYP3A4 poput azolnih antimikotika, inhibitora HIV proteaze, klaritromicina, telitromicina, verapamila,
Marketing Authorisation Holder Daiichi Sankyo Europe GmbH Zielstattstrasse 48 
Nositelj odobrenja za stavljanje lijeka u promet Daiichi Sankyo Europe GmbH Zielstattstrasse 48
Safety in patients with acute coronary syndrome undergoing PCI was evaluated in one clopidogrelcontrolled study (TRITON) in which 6741 patients were treated with prasugrel (60 mg loading dose and 10 mg once daily maintenance dose) for a median of 14.5 months (5802 patients were treated for over 6 months, 4136 patients were treated for more than 1 year). 
Sigurnost prasugrela u bolesnika s akutnim koronarnim sindromom podvrgnutih PCI-u procijenjena je u jednom ispitivanju kontroliranom klopidogrelom (TRITON), u kojemu je 6741 bolesnik liječen prasugrelom (udarna doza od 60 mg i doza održavanja od 10 mg jedanput na dan).
Patients with UA/NSTEMI within 72 hours of symptoms or STEMI between 12 hours to 14 days of symptoms were randomised after knowledge of coronary anatomy. 
Bolesnici koji su imali UA/NSTEMI randomizirani su unutar 72 sata od pojave simptoma, a oni koji su imali STEMI u razdoblju između 12 sati i 14 dana od pojave simptoma, s tim da je kod svih prethodno utvrđena anatomija koronarnog krvožilja.
In healthy subjects, patients with stable atherosclerosis, and patients with ACS receiving Efient, there was no relevant effect of genetic variation in CYP3A5, CYP2B6, CYP2C9, or CYP2C19 on the pharmacokinetics of prasugrel or its inhibition of platelet aggregation. 
Efient nisu zabilježeni značajni učinci genetskih varijacija na CYP3A5, CYP2B6, CYP2C9 ili CYP2C19 na farmakokinetiku prasugrela odnosno na njegov učinak na inhibiciju agregacije trombocita.
Efient 10 mg: Each tablet contains 10 mg of prasugrel (as hydrochloride). 
Efient 10 mg: Jedna tableta sadrži 10 mg prasugrela (u obliku prasugrelklorida).
Tell your doctor if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription, dietary supplements and herbal remedies. 
uključujući i one koje ste nabavili bez recepta te nadomjeske prehrani i biljne lijekove.
Efient is contraindicated in patients with severe hepatic impairment (Child Pugh class C). 
Efient je kontraindiciran u bolesnika s teškim oštećenjem jetre
a 10 mg prasugrel; 5 mg prasugrel if <60 kg 
a10 mg prasugrela; 5 mg prasugrela ako je tjelesna težina <60 kg
Increased frequency (3-fold) and severity of bleeding may occur in patients undergoing CABG surgery within 7 days of discontinuation of prasugrel (see section 4.8). 
U bolesnika koji su podvrgnuti operaciji ugradnje premosnica koronarnih arterija (engl. coronary artery bypass graft, CABG) može se povećati učestalost (trostruko) i težina krvarenja unutar 7 dana od prestanka primjene prasugrela (vidjeti dio 4.8).
Blood and Lymphatic System disorders 
Poremećaji bubrega i mokraćnog sustava hematurija
Thrombocytopaenia Thrombotic thrombocytopaenic purpura (TTP) -see section 4.4 
Poremećaji krvi i limfnog sustava anemija trombocitopenija trombotična trombocitopenična purpura (TTP)vidjeti dio 4.4
c Any intracranial haemorrhage or any clinically overt bleeding associated with a fall in haemoglobin ≥5 g/dL. 
b Svako intrakranijalno krvarenje ili svako klinički zamjetno krvarenje udruženo s padom vrijednosti hemoglobina ≥ 5 g/dl.
Thrombotic Thrombocytopaenic Purpura (TTP) TTP has been reported with the use of prasugrel. 
Trombotična trombocitopenična purpura (TTP)
3.0% (0.5% fatal) 
3,0% (0,5% smrtonosna)
Efient 10 mg film-coated tablets Efient 5 mg film-coated tablets Prasugrel 
Efient 10 mg filmom obložene tablete Efient 5 mg filmom obložene tablete
Adults 
Doziranje Odrasli
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON OF 10 mg FILM-COATED TABLETS 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU KUTIJA ZA 10 mg FILMOM OBLOŽENE TABLETE
Reduced prasugrel efficacy has been seen in patients co-administered prasugrel and morphine (see section 4.5). 
U bolesnika koji su istodobno primali prasugrel i morfin opažena je smanjena djelotvornost prasugrela (vidjeti dio 4.5).
Efient should be initiated with a single 60 mg loading dose and then continued at 10 mg once a day. 
Liječenje lijekom Efient treba započeti jednokratnom udarnom dozom od 60 mg, a zatim nastaviti s
Bleeding Risk Associated with Timing of Loading Dose in NSTEMI In a clinical trial of NSTEMI patients (the ACCOAST study), where patients were scheduled to undergo coronary angiography within 2 to 48 hours after randomization, a prasugrel loading dose given on average 4 hours prior to coronary angiography increased the risk of major and minor peri-procedural bleeding compared with a prasugrel loading dose at the time of PCI. 
U kliničkom ispitivanju u bolesnika s NSTEMI (ispitivanje ACCOAST), u kojem su bolesnici bili podvrgnuti koronarnoj angiografiji unutar 2 do 48 sati nakon randomizacije, udarna doza prasugrela primijenjena prosječno 4 sata prije koronarne angiografije povećala je rizik od značajnog i manjeg krvarenja tijekom postupka u usporedbi s primjenom udarne doze prasugrela u vrijeme perkutane koronarne intervencije.
The incidence of Non-CABG-related TIMI major bleeding, including life-threatening and fatal, as well as TIMI minor bleeding, was statistically significantly higher in subjects treated with prasugrel compared to clopidogrel in the UA/NSTEMI and All ACS populations. 
CABG, uključujući po život opasna i smrtonosna krvarenja, kao i manjih krvarenja (prema TIMI kriterijima) bila je statistički značajno viša u bolesnika liječenih prasugrelom u odnosu na one liječene klopidogrelom u populaciji bolesnika koji su imali UA/NSTEMI kao i u populaciji svih bolesnika s akutnim koronarnim sindromom.
For patients who received their thienopyridine within 3 days prior to CABG, the frequencies of TIMI major or minor bleeding were 26.7% (12 of 45 patients) in the prasugrel group, compared with 5.0% (3 of 60 patients) in the clopidogrel group. 
Među bolesnicima koji su primili tienopiridin unutar 3 dana prije CABG-a, učestalost značajnih ili manjih krvarenja prema TIMI kriterijima iznosila je 26,7% (12 od 45
Efient 5 mg film-coated tablets. 
Efient 5 mg filmom obložene tablete prasugrel
Prasugrel must not be used in patients with severe hepatic impairment (see section 4. 
Prasugrel se ne smije primjenjivati u bolesnika s teškim oštećenjem jetre (vidjeti dio 4.3).
In the phase 3 clinical trial these patients were at greater risk of bleeding, including fatal bleeding, compared to patients <75 years of age. 
U faze III kliničkog ispitivanja ti su bolesnici bili izloženi većem riziku od krvarenja,
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER Daiichi Sankyo Europe GmbH 
11. NAZIV I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET Daiichi Sankyo Europe GmbH
Eye haemorrhage 
Poremećaji oka očno krvarenje
There is limited therapeutic experience in patients with mild and moderate hepatic dysfunction (see section 4.4). 
Terapijsko iskustvo u bolesnika s blagim do umjerenim oštećenjem jetre je ograničeno (vidjeti dio 4.4).
f Clinically overt bleeding associated with a fall in haemoglobin of ≥3 g/dL but <5 g/dL. 
e IKK=intrakranijalno krvarenje f Klinički zamjetno krvarenje udruženo s padom hemoglobina od ≥ 3 g/dl, ali < 5 g/dl.
1.6% (0.2% fatal) 
1,6% (0,2% smrtonosna)
Because of the potential for increased risk of bleeding, chronic NSAIDs (including COX-2 inhibitors) and Efient should be coadministered with caution (see section 4.4). 
NSAIL-ima (uključujući COX-2 inhibitore) (vidjeti dio 4.4).
Requiring inotropes Requiring surgical intervention Requiring transfusion (≥ 4 
Značajno krvarenje prema TIMI c životno ugrožavajućed smrtonosno simptomatsko IKKe potrebna primjena inotropnih lijekova potrebna kirurška intervencija potrebna transfuzija (≥ 4 jedinice)
The mean exposure (AUC) of the active metabolite of prasugrel is approximately 30 to 40% higher in healthy subjects and patients with a body weight of < 60 kg compared to those weighing ≥ 60 kg. Prasugrel should be used with caution in patients with a body weight of < 60 kg due to the potential risk of bleeding in this population (see section 4.4). 
Prosječna izloženost (AUC) aktivnom metabolitu prasugrela je približno 30 do 40% veća u zdravih ispitanika i bolesnika tjelesne težine manje od 60 kg u usporedbi s onima čija je težina ≥ 60 kg.
Bleeding risk 
• iskašljavanje krvi
The maximum inhibition by prasugrel of ADP-induced platelet aggregation is 83% with 5 µM ADP and 79% with 20 µM ADP, in both cases with 89% of healthy subjects and patients with stable atherosclerosis achieving at least 50% inhibition of platelet aggregation by 1 hour. 
Maksimalna inhibicija ADP-om potaknute agregacije trombocita prasugrelom iznosi 83% uz 5 µm ADP-a, odnosno 79% uz 20 µm ADP-a.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON OF 5mg FILM-COATED TABLETS 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU KUTIJA ZA 5 mg FILMOM OBLOŽENE TABLETE
Specifically, prasugrel did not significantly reduce the frequency of the composite endpoint of cardiovascular (CV) death, myocardial infarction (MI), stroke, urgent revascularization (UR), or glycoprotein (GP) IIb/IIIa inhibitor bailout through 7 days from randomization in subjects receiving prasugrel prior to coronary angiography compared to patients receiving the full loading dose of prasugrel at the time of PCI, and the rate of the key safety objective for all TIMI major bleeding (CABG and non-CABG events) through 7 days from randomization in all treated subjects was significantly higher in subjects receiving prasugrel prior to coronary angiography versus patients receiving the full loading dose of prasugrel at the time of PCI. 
Konkretno, u ispitanika koji su primili prasugrel prije koronarne angiografije, prasugrel tijekom 7 dana nakon randomizacije nije značajno smanjio učestalost objedinjene mjere ishoda, koja je uključivala kardiovaskularnu smrt, infarkt miokarda, moždani udar, hitnu revaskularizaciju ili hitno liječenje inhibitorom glikoproteina IIb/IIIa, u usporedbi s bolesnicima koji su primili cijelu udarnu dozu prasugrela u vrijeme perkutane koronarne intervencije.
Patients ≥ 75 years old Non-CABG-related TIMI major or minor bleeding rates: 
Bolesnici u dobi od ≥ 75 godina ili oni čija je tjelesna težina manja od
Efient 5 mg: The tablets are yellow and double-arrow-shaped, with “5 MG” debossed on one side and “4760” on the other. 
Efient 5 mg: Tablete su žute boje u obliku dvostruke strelice, s utisnutom oznakom "5 mg" na jednoj i "4760" na drugoj strani.
United Kingdom Daiichi Sankyo UK Ltd Tel: +44 (0) 800 028 5122 
United Kingdom Daiichi Sankyo UK Ltd Tel: +44 (0) 800 028 5122 Ova uputa je zadnji puta revidirana u {MM/GGGG}.
6.5% (0.3% fatal) 
6,5% (0,3% smrtonosna)
Bleeding Risk Associated with Timing of Loading Dose in NSTEMI In a clinical study of NSTEMI patients (the ACCOAST study), where patients were scheduled to undergo coronary angiography within 2 to 48 hours after randomization, patients given a 30 mg loading dose on average 4 hours prior to coronary angiography followed by a 30 mg loading dose at the time of PCI had an increased risk of non-CABG peri-procedural bleeding and no additional benefit compared to patients receiving a 60 mg loading dose at the time of PCI (see sections 4.2 and 4.4). 
Rizik od krvarenja povezan s vremenom primjene udarne doze kod NSTEMI U kliničkom ispitivanju u bolesnika s NSTEMI (ispitivanje ACCOAST), u kojem su bolesnici bili podvrgnuti koronarnoj angiografiji unutar 2 do 48 sati nakon randomizacije, bolesnici koji su primili udarnu dozu od 30 mg u prosjeku 4 sata prije koronarne angiografije te zatim udarnu dozu od 30 mg u vrijeme perkutane koronarne intervencije imali su povećan rizik od krvarenja nevezanog za CABG
Iron oxide red (E172) {only Efient 10 mg} Iron oxide yellow (E172) Talc 
Film ovojnica: laktoza hidrat hipromeloza (E464) titanijev dioksid (E171) triacetin (E1518) željezov oksid, crveni (E172) {samo Efient 10 mg} željezov oksid, žuti (E172) talk
2.9% (0.1% fatal) 
2,9% (0,1% smrtonosna)
Efient 10 mg: The tablets are beige and double-arrow-shaped, with “10 MG” debossed on one side and “4759” on the other. 
Efient 10 mg: Tablete su bež boje u obliku dvostruke strelice, s utisnutom oznakom "10 mg" na jednoj i "4759" na drugoj strani.
3.3% (0.1% fatal) 
3,3% (0,1% smrtonosna)
6.9% (0.1% fatal) 
6,9% (0,1% smrtonosna)
Nonfatal stroke 
Incidencija tumora
A delayed and decreased exposure to oral P2Y12 inhibitors, including prasugrel and its active metabolite, has been observed in patients with acute coronary syndrome treated with morphine. 
U bolesnika s akutnim koronarnim sindromom koji se liječe morfinom opažena je odgođena i smanjena izloženost oralnim inhibitorima P2Y12, uključujući prasugrel i njegov aktivni metabolit.
Requiring inotropes 
Prijavljivanje nuspojava
Requiring transfusion (≥4 units) TIMI Minor bleedinge aOther standard therapies were used as appropriate. 
Značajno krvarenje prema TIMIb životno ugrožavajućec smrtonosno simptomatsko IKKd potrebna primjena inotropnih lijekova potrebna kirurška intervencija potrebna transfuzija (≥ 4 jedinice) Manje krvarenje prema TIMI kriterijimae a Druge standardne terapije primijenjene su po potrebi.
Each tablet contains 5 mg prasugrel (as hydrochloride). 
Jedna tableta sadrži 5 mg prasugrela (u obliku prasugrelklorida).
History of TIA or stroke 
TIA ili moždani udar u anamnezi
Your doctor should prescribe a daily dose of 5 mg as there is a greater risk of bleeding in patients older than 75 years - a recent serious injury - recent surgery (including some dental procedures) - recent or recurrent bleeding from the stomach or intestines (e.g. a stomach ulcer or colon polyps) - body weight of less than 60 kg. 
- ako ste nedavno imali operaciju (uključujući i neke stomatološke zahvate) - ako ste nedavno krvarili iz želuca ili crijeva ili često imate takva krvarenja (npr. želučani vrijed ili crijevne polipe) - ako Vam je tjelesna težina manja od 60 kg.
Only take other medicines while you are on Efient if your doctor tells you that you can. 
Za vrijeme liječenja lijekom Efient druge lijekove smijete uzimati samo uz odobrenje liječnika.
2.2% (0.3% fatal) 
2,2% (0,3% smrtonosna)
4.2% (0.3% fatal) 
4,2% (0,3% smrtonosna)
Patients ≥75 years old or those below 60 kg (N=3022) were randomized to 5 mg prasugrel. 
60 kg (N=3022) randomizirani su u skupinu koja je primala prasugrel u dozi od 5 mg.
Prasugrel 5 mg provided greater antiplatelet effect than clopidogrel 75 mg. Prasugrel should be used with caution in patients ≥ 75 years old and in patients weighing <60 kg (see sections 4.2, 4.4 and 4.8). 
Prasugrel treba primjenjivati uz oprez u bolesnika u dobi od ≥ 75 godina te u bolesnika tjelesne težine < 60 kg (vidjeti dijelove 4.2, 4.4 i 4.8).
Monitoring for signs of hypersensitivity in patients with a known allergy to thienopyridines is advised (see section 4.8). 
Preporučuje se nadzor bolesnika s poznatom alergijom na tienopiridine kako bi se uočili znakovi preosjetljivosti
In the phase 3 clinical trial (TRITON) key exclusion criteria included an increased risk of bleeding; anaemia; thrombocytopaenia; a history of pathological intracranial findings. 
povećan rizik od krvarenja, anemija, trombocitopenija te patološki intrakranijalni nalazi u anamnezi.
Each tablet contains 10 mg prasugrel (as hydrochloride). 
Jedna tableta sadrži 10 mg prasugrela (u obliku prasugrelklorida).
No dosage adjustment is necessary for patients with renal impairment, including patients with end stage renal disease (ESRD). 
Oštećenje bubrega: Nije potrebno prilagođavati dozu u bolesnika s oštećenjem bubrega, uključujući i bolesnike u terminalnoj fazi bubrežne bolesti.
1.4% (0.1% fatal) 
1,4% (0,1% smrtonosna)
eClinically overt bleeding associated with a fall in haemoglobin of ≥3 g/dL but <5 g/dL. 
dIKK=intrakranijalno krvarenje e Klinički zamjetno krvarenje udruženo s padom vrijednosti hemoglobina od ≥3 g/dl ali <5 g/dl.
• Bruising 
• modrice
• Bleeding from your rectum, blood in your stools or black stools. 
• krvarenje iz završnog dijela debelog crijeva, krv u stolici ili crnu stolicu • krvarenje koje ne možete zaustaviti, npr. iz posjekotine
Hepatic impairment 
Oštećenje bubrega
No dose adjustment is necessary for patients with mild to moderate impaired hepatic function (Child Pugh Class A and B). 
Oštećenje jetre: Nije potrebno prilagođavati dozu u osoba s blagim do umjerenim oštećenjem jetrene funkcije (Child
Magyarország Lilly Hungária Kft. Tel: + 36 1 328 5100 
Eli Lilly Hrvatska d.o.o. Tel: +385 1 2350 999
Haematuria 
pvrijednost
Higher inhibition of platelet aggregation was observed in patients switched to prasugrel 10 mg compared with those treated with clopidogrel 150 mg. 
10 mg u odnosu na one liječene klopidogrelom u dozi od 150 mg.
o Severe haemorrhagic events are more frequent in patients ≥ 75 years of age (including fatal events) or those weighing < 60 kg o Treatment with prasugrel is generally not recommended for patients of ≥ 75 years of age. 
o su epizode značajnog krvarenja češće u bolesnika u dobi od ≥ 75 godina (uključujući i smrtonosna krvarenja) te onih tjelesne težine < 60 kg.
• Before you are taking Efient: 
Upozorenja i mjere opreza • Prije nego uzmete Efient:
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 5 mg prasugrel (as hydrochloride) 
NAVOĐENJE DJELATNE(IH) TVARI Jedna tableta sadrži 5 mg prasugrela (u obliku prasugrelklorida).
1.3% (0.1% fatal) 
1,3% (0,1% smrtonosna)
Mean steady-state inhibition of platelet aggregation was 74% and 69% respectively for 5 µM ADP and 20 µM ADP, and was achieved following 3 to 5 days of administration of the 10 mg prasugrel maintenance dose preceded by a 60 mg loading dose. 
Stanje dinamičke ravnoteže postignuto je nakon 3-5 dana primjene doze održavanja od 10 mg prasugrela, kojoj je prethodila udarna doza od 60 mg.
Requiring surgical intervention 
Kirurški zahvat